Gemalto joins SAFE-BioPharma Association

23 April 2009

Gemalto, a supplier of digital security systems, has become a vendor partner of SAFE-BioPharma Association.

Gemalto is joining with biopharmaceutical and healthcare industry leaders to help the industry achieve its common goal of a fully electronic business environment by 2012. Gemalto will contribute its expertise in smart card-based solutions for authentication, network security and digital signature.

Gemalto is the first smart card provider to join SAFE-BioPharma. Gemalto has been an active industry partner since 2004, when it began working with Pfizer to implement smart card employee badges that converge physical and logical access control onto a single identity credential. Gemalto is also a leading supplier of smart card based solutions for healthcare identity management worldwide.

The SAFE-BioPharma Association, based in Fort Lee, New Jersey, is a non-profit association that created and manages the SAFE-BioPharma digital identity and signature standard for the pharmaceutical and healthcare industries. The standard provides users with a secure, enforceable, and regulatory compliant way to verify identities of parties involved in electronic transactions and to apply their digital signatures to electronic documents.

“We welcome Gemalto to the growing SAFE-BioPharma vendor partner community. The company's broad experience in smart cards, digital security, digital signature and identity management for healthcare, makes it a valuable global resource for life science companies,” said Mollie Shields-Uehling, president and chief executive officer, SAFE-BioPharma Association.

“Gemalto is a natural partner to companies using the SAFE-BioPharma standard, because we provide smart cards and tokens that serve as the secure carriers for digital identities. Two factor authentication (something you have and something you know) is an important building block for the success of many of the proposed Health IT initiatives underway in the US. For citizens to benefit from the new technologies, they need to be assured their privacy is protected,” said François Lasnier, vice president and general manager, Security, for Gemalto North America.

SAFE-BioPharma Association (www.safe-biopharma.org)

SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma digital identity and signature standard for the pharmaceutical and healthcare industries.


The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions.

It facilitates interoperability by providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE-BioPharma’s vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012.

The Association’s members include:

  • Abbott (NYSE: ABT)
  • Amgen (NASDAQ: AMGN)
  • AstraZeneca (NYSE: AZN)
  • Bristol-Myers Squibb (NYSE:BMY)
  • GlaxoSmithKline (NYSE: GSK)
  • Johnson & Johnson (NYSE: JNJ)
  • Eli Lilly (NYSE: LLY)
  • Merck (NYSE:MRK)
  • National Notary Association
  • Organon (NYSE: SGP)
  • Pfizer (NYSE: PFE)
  • Premier Inc.
  • Procter & Gamble (NYSE: PG)
  • Roche
  • Sanofi-Aventis (NYSE:SNY).

Bookmark this paget>

To top